[Prognostic significance of cyclooxygenase (COX-1 and COX-2) expression in endometrial carcinoma (clinical and immunohistochemical study)].
An immunohistochemical study of 100 endometrial adenocarcinomas assessed expression of COX-1 (40%) and COX-2 (72%) cyclooxygenases. An inverse correlation between COX-2 expression and tumor cell differentiation was matched by a direct one between COX-2 expression and survival. In cases of no expression, overall relapse-free 5-year survival was 92 and 88%, respectively, while distinct expression was associated with 52 and 48%, respectively (p = 0.0004; 0.0005). Similar relationships were reported for COX-1, although the significance was lower (p = 0.02). Since the differences in survival vis-a-vis clinico-morphological features were insignificant, except for COX-1, COX-2 expression, the latter characteristics should be regarded as independent prognosticators, much more superior to such traditional factors as stage and cell differentiation.
Boldarian
N A
NA
Pozharisskiĭ
K M
KM
Vinokurov
V L
VL
Ten
V P
VP
Samsonova
E A
EA
D000230:Adenocarcinoma / Q000201:enzymology*; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D002454:Cell Differentiation; D051545:Cyclooxygenase 1 / Q000032:analysis*; D051546:Cyclooxygenase 2 / Q000032:analysis*; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000201:enzymology*; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2